Cancer Family
Malignant Respiratory System Neoplasm
CI-CAN-00000249Explore in graph →
2,650 active trials51 approved drugs619 evidence items
- NCIt
- C4571
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000249Explore in graph →
Clinical trials
11,130 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,492)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05146219 | Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation | completed | Phase 2 | 29 | TYK Medicines, IncINDUSTRY | 1 | Dec 30, 2024 | clinicaltrials |
| NCT04731467 | A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 79 | Famewave Ltd.INDUSTRY | 3 | Dec 27, 2024 | clinicaltrials |
| NCT04795245 |
| completed |
| — |
| 805 |
| Boehringer IngelheimINDUSTRY |
| 1 |
| Dec 27, 2024 |
| clinicaltrials |
| NCT06746948 | Dyadic Psychological Stress Among Lung Cancer Patient-caregiver Dyads | completed | — | 254 | Central South UniversityOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT03997968 | A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 169 | Cyteir Therapeutics, Inc.INDUSTRY | 1 | Dec 24, 2024 | clinicaltrials |
| NCT06747026 | Real-World Immuno-Radiotherapy for Advanced NSCLC(OCEANUS) | completed | — | 338 | Fengming KongOTHER | 1 | Dec 24, 2024 | clinicaltrials |
| NCT03043599 | Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 21 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT04541706 | Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India | completed | Phase 4 | 100 | PfizerINDUSTRY | 1 | Dec 20, 2024 | clinicaltrials |
| NCT01463423 | Individualized Lung Tumor Stereotactic Ablative Radiotherapy (iSABR) | completed | N/A | 256 | Stanford UniversityOTHER | 3 | Dec 19, 2024 | clinicaltrials |
| NCT06737367 | Integrating Machine Learning for Prognostic Prediction in Stage I NSCLC by CT Images and Pathological Factors(Stage I NSCLC) | completed | — | 800 | Jinling Hospital, ChinaOTHER | 1 | Dec 19, 2024 | clinicaltrials |
| NCT04028479 | The Registry of Oncology Outcomes Associated With Testing and Treatment(ROOT) | completed | — | 167 | Taproot HealthINDUSTRY | 1 | Dec 18, 2024 | clinicaltrials |
| NCT03232138 | Clinical Trial of Lung Cancer Chemoprevention With Sulforaphane in Former Smokers | completed | Phase 2 | 43 | Jian-Min Yuan, MDOTHER | 1 | Dec 17, 2024 | clinicaltrials |
| NCT03656549 | Dose Individualization of Pemetrexed - IMPROVE-I(IMPROVE-I) | completed | Phase 4 | 6 | Radboud University Medical CenterOTHER | 1 | Dec 17, 2024 | clinicaltrials |
| NCT01789099 | A Phase I/IIa Study of UV1 Vaccination in Patients With Non Small Cell Lung Cancer.(UV1-hTERT2012L) | completed | Phase 1 / Phase 2 | 18 | Ultimovacs ASAINDUSTRY | 1 | Dec 16, 2024 | clinicaltrials |
| NCT02754882 | A Study Comparing SB8 and Avastin® in Patients With Advanced Non-squamous Non-small Cell Lung Cancer | completed | Phase 3 | 763 | Samsung Bioepis Co., Ltd.INDUSTRY | 13 | Dec 16, 2024 | clinicaltrials |
| NCT03518554 | A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors | completed | Phase 1 | 38 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Dec 16, 2024 | clinicaltrials |
| NCT05462795 | Liquid Biopsy for Early Non-small Lung Cancer Detection | completed | — | 171 | University of ArizonaOTHER | 1 | Dec 16, 2024 | clinicaltrials |
| NCT05933863 | Molecular Subtyping of Extensive Stage Small Cell Lung Cancer and Relevent Clinical Significance(MOSAIC) | completed | — | 168 | Peking University Cancer Hospital & InstituteOTHER | 1 | Dec 16, 2024 | clinicaltrials |
| NCT06735781 | Clinical Outcomes of Patients With Resectable Non-Small Cell Lung Cancer Receiving Neoadjuvant Nivolumab Plus Chemotherapy in France | completed | — | 101 | Bristol-Myers SquibbINDUSTRY | 1 | Dec 16, 2024 | clinicaltrials |
| NCT05926180 | Assessing the Effect of DZD9008 on the Pharmacokinetics of the Cocktail Probes Representative for CYP3A4, P-gp, BCRP and OATP1B1 in Patients with EGFR or HER2 Mutant Advanced Non-small Cell Lung Cancer (WU-KONG19) | completed | Phase 1 | 25 | Dizal PharmaceuticalsINDUSTRY | 1 | Dec 13, 2024 | clinicaltrials |
| NCT00478699 | Randomized Customized Adjuvant Chemotherapy (GECP-SCAT)(GECP-SCAT) | completed | Phase 3 | 500 | Spanish Lung Cancer GroupOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT04946019 | MR-Linac Guided Adaptive FSRT for Brain Metastases From Non-small Cell Lung Cancer | completed | Phase 2 | 55 | Sun Yat-sen UniversityOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT02108964 | A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies | completed | Phase 1 / Phase 2 | 225 | Novartis PharmaceuticalsINDUSTRY | 9 | Dec 11, 2024 | clinicaltrials |
| NCT02175017 | ONO-4538 Study in Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 104 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT03846310 | A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer(ARC-4) | completed | Phase 1 | 77 | Arcus Biosciences, Inc.INDUSTRY | 4 | Dec 9, 2024 | clinicaltrials |
| NCT04830813 | Phase 3 Clinical Study of Chiauranib Capsule in Patients With Small-cell Lung Cancer | completed | Phase 3 | 184 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT06557967 | Study on Prevalence and Impact of Brain Metastases on Survival in Lung Cancer by Line of Treatment | completed | — | 22,517 | Daiichi SankyoINDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT04238130 | Evaluation ctDNA in Patients of Non-Small-Cell Lung Cancer Following Resection(EVOLUTION) | completed | — | 132 | Sun Yat-sen UniversityOTHER | 1 | Dec 6, 2024 | clinicaltrials |
| NCT03809169 | Peripheral EBUS With ROSE vs no ROSE; Slim Bronchoscope Without Guide Sheath vs Standard Bronchoscope With Guide Sheath | completed | N/A | 186 | University of CalgaryOTHER | 1 | Dec 5, 2024 | clinicaltrials |
| NCT03995875 | Real World Evidence of Long-term Safety and Efficacy in Patients Treated With Durvalumab After Concurrent Chemoradiation for Unresectable Stage III NSCLC(AYAME) | completed | — | 529 | AstraZenecaINDUSTRY | 1 | Dec 5, 2024 | clinicaltrials |
| NCT04691388 | A Trial of Sintilimab Plus Anlotinib For Metastatic NSCLC After First-Line PD-1 Inhibitor | completed | Phase 2 | 29 | Zhejiang Cancer HospitalOTHER | 1 | Dec 5, 2024 | clinicaltrials |
| NCT03081689 | Neo-Adjuvant Immunotherapy With Nivolumab for Non Small Cell Lung Cancer Patients | completed | Phase 2 | 46 | Spanish Lung Cancer GroupOTHER | 1 | Dec 4, 2024 | clinicaltrials |
| NCT03134456 | Pembrolizumab for Metastatic NSCLC Patients Expressing PD-L1 Who Have Their Own PDX | completed | Phase 4 | 50 | Samsung Medical CenterOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT06457269 | Evaluating the Potential of Large Language Models for Respiratory Disease Consultations(EPLLMMRDC) | completed | N/A | 703 | North Sichuan Medical CollegeOTHER | 1 | Nov 27, 2024 | clinicaltrials |
| NCT04629300 | Supportive Care Mobile Application for Patients With NSCLC | completed | N/A | 120 | Massachusetts General HospitalOTHER | 1 | Nov 22, 2024 | clinicaltrials |
| NCT02135679 | The Detection Of Circulating Tumor Cells (CTC) In Patients With NSCLC Undergoing Definitive Radiotherapy Or Chemoradiotherapy | completed | — | 204 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT02613507 | Efficacy Study of Nivolumab Compared to Docetaxel in Subjects Previously Treated With Advanced or Metastatic Non Small Cell Lung Cancer(CheckMate 078) | completed | Phase 3 | 504 | Bristol-Myers SquibbINDUSTRY | 4 | Nov 19, 2024 | clinicaltrials |
| NCT03761914 | Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers | completed | Phase 1 / Phase 2 | 26 | Sellas Life Sciences GroupINDUSTRY | 1 | Nov 19, 2024 | clinicaltrials |
| NCT02113813 | A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations | completed | Phase 1 | 133 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Nov 14, 2024 | clinicaltrials |
| NCT03413449 | A Prospective Study Frailty for Esophagectomy and Lung Resection in Thoracic Surgery | completed | — | 360 | The Cleveland ClinicOTHER | 1 | Nov 14, 2024 | clinicaltrials |
| NCT05807893 | Study to Evaluate the Safety and Efficacy of Serplulimab Plus Bevacizumab and Chemotherapy in NSCLC Patients With Brain Metastases(SUPER BRAIN) | completed | Phase 2 / Phase 3 | 40 | Sun Yat-sen UniversityOTHER | 1 | Nov 13, 2024 | clinicaltrials |
| NCT03285893 | Oral Cell DNA Adducts in Smokers(OCDNA) | completed | — | 281 | University of MinnesotaOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT04416633 | Study to Access Safety of Durvalumab in Indian Adult Patients With Locally Advanced NSCLC | completed | Phase 4 | 100 | AstraZenecaINDUSTRY | 1 | Nov 8, 2024 | clinicaltrials |
| NCT04855929 | A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients with Advanced Cancer.(ANV419-001) | completed | Phase 1 | 55 | Anaveon AGINDUSTRY | 3 | Nov 8, 2024 | clinicaltrials |
| NCT04859400 | Influence of a Home-based Nutrition and Exercise Program on Quality of Life of Palliative Cancer Outpatients | completed | N/A | 72 | Kantonsspital Winterthur KSWOTHER | 2 | Nov 8, 2024 | clinicaltrials |
| NCT05048082 | A Study to Evaluate Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Lung Malignancies | completed | Phase 2 | 24 | OncoNano Medicine, Inc.INDUSTRY | 1 | Nov 8, 2024 | clinicaltrials |
| NCT02488850 | Determination of Peripheral Immune Cell Activity During Treatment With Either Surgery or Radiotherapy in Patients With Early Stage NSCLC(HAMLET) | completed | N/A | 32 | Erasmus Medical CenterOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT04920981 | Atezolizumab Combined With Chemotherapy in Extensive Stage SCLC(CLINATEZO) | completed | — | 518 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Nov 7, 2024 | clinicaltrials |
Data updated 24 days agoSource updated Dec 30, 2024source: clinicaltrials